MedTrace Logo

Autologous Adipose Derived MSCs Transplantation in Patient With Spinal Cord Injury.

NCT01274975 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2014-03-26

No results posted yet for this study

Summary

This study is designed to assess the safety of intravenous autologous adipose derived mesenchymal stem cells transplant in spinal cord injury patients.

Conditions

  • Spinal Cord Injury

Interventions

OTHER

Autologous Adipose Derived Mesenchymal Stem Cells

Intravenous infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4 x 10e8 cells

Sponsors & Collaborators

  • R-Bio

    lead INDUSTRY

Principal Investigators

  • SangHan Kim, MD · Anyang Sam Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-11-30
Completion
2010-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01274975 on ClinicalTrials.gov